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Abstract: Chronic lymphocytic leukemia (CLL) is an indolent but incurable disease. Despite 
the improvement of the available therapies, the management of heavily-treated CLL patients 
represents a challenge for modern practitioners. Ofatumumab is a second-generation, fully 
human anti-CD20 monoclonal antibody that has shown activity in CLL patients who have failed 
very effective therapies such as fludarabine, alemtuzumab and rituximab. Potential benefits of 
ofatumumab include powerful complement-dependent cytotoxicity, less immunogenicity, faster 
infusions and activity in resistant CLL patients. Recently, the FDA has approved ofatumumab for 
the treatment of CLL patients who have failed fludarabine and alemtuzumab-based regimens. The 
aim of this review is to summarize the current knowledge regarding pharmacology, mechanism 
of action, pre-clinical and clinical development, and the role of ofatumumab for the treatment 
of CLL patients who have failed previous therapies. Further research is necessary to further 
define the role of ofatumumab in the treatment of CLL.
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Introduction
Management issues in the treatment of CLL
Chronic lymphocytic leukemia (CLL) is a malignant lymphoproliferative disease that 
originates from a clonal proliferation of malignant B-lymphocytes. CLL is considered 
the most common adult leukemia in the Western Hemisphere and it tends to affect 
males more frequently than females. In 2009, it was estimated that there were 15,490 
new cases diagnosed with 4390 associated deaths in the United States.1 The median 
age of presentation is 70 years, with a steady increase in risk of developing CLL with 
increasing age.
The clinical course of CLL is highly variable. Many patients are diagnosed at 
early, asymptomatic phases of the disease and are managed by expectant surveillance.2 
A substantial portion of patients, however, will eventually need therapy and the course 
of their disease will be characterized by episodes of remissions and relapses that can last 
for several years. A smaller subset of patients will have high-risk or refractory disease 
with survival of only a few years. The clinical presentation of CLL has been linked with 
prognostic significance; early stage disease has an estimated life expectancy of greater 
than 10 years and advanced stage disease has an estimated life expectancy of 18 months 
to 3 years. The final prognosis of CLL patients has been linked to the presence of several 
features, including immunoglobulin variable region heavy-chain (IgVH) mutational 
status, expression of CD38 and/or ZAP-70, and cytogenetic abnormalities.3Journal of Blood Medicine 2010:1
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The diagnosis of CLL is established by the presence of 
B-cell lymphocytosis of greater than 5000 cells/µL in the 
peripheral blood for more than 3 months.2 The leukemic cells 
are small, mature-appearing lymphocytes with scant cyto-
plasm and dense nuclei lacking discernible nucleoli. The char-
acteristic immunophenotype of CLL shows a coexpression of 
CD5, a T-cell antigen, and the B-cell antigens CD19, CD20 
and CD23. The levels of expression of CD20 and CD79b are 
characteristically low when compared to normal mature B-cell 
populations.4 The monoclonality of the population can be 
determined by surface immunoglobulin light chain restriction, 
detection of clonal cytogenetic abnormalities and/or clonal 
immunoglobulin gene rearrangements. In 80% of the cases, 
molecular genetic lesions can be detected at time of diagnosis. 
Common genetic abnormalities found in CLL include 13q 
deletion, trisomy 12 and 11q and 17p deletions; deletions in 
11q and 17p are associated with poorer prognosis.5
Currently there are 4 drugs approved by the Food and Drug 
Administration (FDA) for use in patients with CLL: chloram-
bucil (Leukeran®; GlaxoSmithKline, Research Triangle Park, 
NC, USA), fludarabine (Fludara®; Ben Venue Laboratories, 
Bedford, OH, USA), bendamustine (Treanda®; Cephalon 
Inc., Frazer, PA, USA) and alemtuzumab (Campath®; Gen-
zyme Corporation, Cambridge, MA, USA). Chlorambucil, 
an alkylating agent, was the first drug approved for CLL 
and is effective on inducing responses lasting for 1 to 2 
years. Fludarabine has achieved higher response rates than 
chlorambucil in randomized controlled trials; however, the 
benefit on progression-free survival (PFS) in the elderly is 
less clear.6 Fludarabine is also associated with higher rates 
of severe infections and neutropenia.7 Bendamustine has 
shown to be superior to chlorambucil in obtaining clinical 
responses and prolonging PFS with an acceptable toxicity 
profile.8 Alemtuzumab is an anti-CD52 monoclonal antibody 
(MAb) approved as frontline and second-line therapy for 
CLL. Alemtuzumab has shown efficacy in high-risk patients 
carrying 17p deletions9,10 and to eradicate minimal residual 
disease.11 Unfortunately, alemtuzumab is associated with 
profound myelo and immunosuppression resulting in an 
increased rate of infections such as CMV reactivation.12
Rituximab (Rituxan®; Genentech, South San Francisco, 
CA, USA) is a chimeric antiCD20 MAb and, although is 
not FDA-approved, it is the MAb most commonly used in 
CLL and has shown improvements in overall response rates 
(ORR) and progression-free survival (PFS) when added to 
chemotherapy in large randomized trials.13,14 The response 
to rituximab, however, seems to decrease with subsequent 
rituximab-containing regimens and, although rarely, the 
administration of rituximab has been associated with 
life-threatening adverse events, such as anaphylactic and 
severe mucocutaneous reactions.
Newer agents that have shown efficacy in CLL are flavo-
piridol and lenalidomide. Flavopiridol is a cyclin-dependent 
kinase inhibitor that showed efficacy on inducing apoptosis 
in CLL lines.15 In a recent phase II trial, flavopiridol induced 
responses in 53% of the treated patients with a median 
overall survival (OS) of 8.6 months.16 The most common 
grade 3–4 adverse events were neutropenia (81%), diarrhea 
(72%), tumor lysis syndrome (22%) and liver enzymes lev-
els elevation (34%). Lenalidomide is an immunomodulator 
agent with a wide antitumor activity, which has shown to 
alter cytokine production, modulate effector cell responses 
and directly induce apoptosis in malignant cells.17,18 A phase 
II trial in relapsed or refractory CLL showed an ORR of 
47% with a median OS that was not reached at the time of 
publication.19 The most common grade 3 or 4 adverse events 
were neutropenia (70%), thrombocytopenia (45%), flare 
reaction (8%), pulmonary embolism (5%) and tumor lysis 
syndrome (5%).
Despite newer drug options, the disease remains incurable 
with current standard therapies. Over the last decade, prospec-
tive, randomized trials have analyzed various combinations 
of nucleoside analogues, alkylating agents and MAbs for the 
treatment of CLL. It has been demonstrated that as additional 
agents were added to a fludarabine-based regimen, response 
rates, with ORR and complete response (CR) rates in excess 
of 90% and 50%, respectively, and PFS have improved; how-
ever, improved response rates have not translated into longer 
OS (see Tables 1 and 2 for selected CLL regimens used in the 
front-line and relapsed settings, respectively).
Areas of investigation to improve the current therapy 
include patient populations with high-risk disease, based 
on IgVH mutational status, ZAP-70 and/or CD38 expres-
sion and molecular cytogenetics, and those with relapsed 
or refractory disease. Patients that have become resistant to 
fludarabine and alemtuzumab-based regimens, also called 
double refractory (DR), have an associated median survival 
of less than 1 year, low response rates to salvage therapy and 
increased rate of adverse events.20 In a similar manner, bulky 
fludarabine-resistant disease (BFR) has also been associated 
with poor responses, reduced survival and increased rate of 
toxicity, mainly of an infectious nature.20
role of ofatumumab
To address the need for improved response and overall 
survival rates, many other agents have been evaluated. Journal of Blood Medicine 2010:1
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Ofatumumab (Arzerra®; GlaxoSmithKline, Collegeville, 
PA, USA and Genmab, Copenhagen, Denmark) is a 
second-generation, fully human antiCD20 MAb whose 
target epitope is distinct from rituximab. Several clini-
cal trials in patients with relapsed DR or BFR CLL have 
demonstrated promising response rates with a safe toxic-
ity profile and have established ofatumumab as a possible 
therapeutic option. The aim of this paper is to summarize 
the current knowledge and discuss potential applications 
of ofatumumab in patients with relapsed CLL who have 
failed previous therapies.
Review of pharmacology, mode  
of action, pharmacokinetics  
of ofatumumab
Ofatumumab is an IgG1, fully human, second-generation 
antiCD20 MAb with a molecular weight of 150 kDA. It was 
produced by immunizing HCo7 and KM mice with a murine 
cell line transfected with human heavy and light chain genes. 
MAbs exert their therapeutic effect by enhancing antigen-
dependent cellular cytotoxicity (ADCC) and complement-
dependent cytotoxicity (CDC) while inducing apoptotic 
Table  Selected regimens used as first-line therapy in chronic lymphocytic leukemia
Author Regimen No patients ORR/CR Progression-free survival Overall survival
rai7 Fludarabine (F) 170 63%/20% Median 20 months Median 66 months (NS)
Chlorambucil 181 37%/4% Median 14 months Median 55 months
Hillmen36 Alemtuzumab (A) 149 83%/24% Median 14.6 months 2-year 84% (NS)
Chlorambucil 148 55%/2% Median 11.7 months 2-year 84%
Knauf  8 Bendamustine (B) 162 68%/31% Median 21.6 months NS
Chlorambucil 157 31%/2% Median 8.3 months NS
Hallek13,37 FCr 408 95%/44% Median 52 months 3-year 84%
FC 409 88%/22% Median 33 months 3-year 79%
robak38 CM + cladribine 163 80%/36% Median 23 months Median not reached (NS)
C + cladribine 171 83%/29% Median 22 months Median not reached
Cladribine 174 77%/21% Median 23 months Median 51 months
Kay39 PCr 65 91%/41% Median 32.6 months Nr
Parikh40 CFAr 60 92%/70% 2-year 68% Nr
Fischer41 Br 117 91%/33% Median not reached Nr
Abbreviations: C, cyclophosphamide; R, rituximab; M, mitoxantrone; ORR, overall response rate; CR, complete response; NS, not statistically significant; NR, not reported.
Table  Selected regimens used in relapsed or refractory chronic lymphocytic leukemia
Author  Regimen  # Patients  ORR/CR  Progression-Free 
Survival
Overall Survival 
robak14 FCr 276 70%/24% Median 31 months Median not reached (NS)
FC 276 58%/13% Median 21 months Median 53 months
O’Brien42,43 FC + oblimersen 120 Nr/9% Nr 5-year 25% (NS)
FC 121 Nr/3% Nr 5-year 15%
Fischer44 Br 81 77%/15% Nr Nr
Byrd45 FCr + lumiliximab 31 65%/52% Median 19 months Nr
Lamanna46 PCr 32 75%/25% Nr Median 44 months
Lin16 Flavopiridol 64 53%/2% Median 9 months Nr
Chanan-Khan19 Lenalidomide 45 47%/9% Median not reached Nr
Coiffier27 Ofatumumab 33 42%/Nr Nr Nr
Kipps30 Ofatumumab 138 47%–58%/Nr Nr Median 14–15 months
wierda32 FC + ofatumumab 61 73%–77%/32%–50% Median not reached Nr
Abbreviations: F, fludarabine; C, cyclophosphamide; R, rituximab; B, bendamustine; P, pentostatin; ORR, overall response rate; CR, complete response; NS, not statistically 
significant; NR, not reported.Journal of Blood Medicine 2010:1
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pathways within the target cells.21 Ofatumumab binds to 
a different epitope on the CD20 molecule than rituximab, 
which is located on the smaller extracellular loop of CD20 
(Figure 1) and then releases very slowly from the target 
(reduced off-rates).22 These two characteristics are thought 
to be the etiology of its higher efficacy when compared to 
rituximab in pre-clinical models.
Teeling and colleagues demonstrated that ofatumumab 
was able to stimulate cell killing when incubated with 
plasma alone, therefore confirming its role as a strong 
CDC inducer. Furthermore, cell killing was blunted after 
heat-induced complement inactivation. In this same study, 
the group demonstrated that rituximab mixed with CLL 
cells with low CD20 expression (Raji) showed no activity, 
while ofatumumab when exposed to Raji cells demonstrated 
activity.23
A follow-up study compared the required CD20 
concentrations for activity between rituximab and 
ofatumumab.24 The results of their analysis established that 
ofatumumab achieved full lysis with CD20 concentrations 
as low as 4,500 molecules compared with rituximab, which 
required at least 30,000 molecules to be active. As part of 
this study, on- and off-rates of rituximab and ofatumumab 
were compared. The on-rates were similar with both MAbs 
but the off-rates were longer with ofatumumab. Finally, when 
blocking the A170/P172 epitope, the rituximab binding site 
located in the extracellular domain of the large loop of the 
CD20 molecule, the effect of ofatumumab was not affected. 
From these studies, the authors concluded that the ability of 
ofatumumab to elicit a stronger CDC should be associated to 
the recognition of a different form of CD20 or the possible 
binding to a different epitope within the CD20 molecule. 
Using epitope mapping, ofatumumab showed binding to 
an epitope located in the extracellular domain of the small 
loop of CD20.
Beum and colleagues, using a microscopic analysis in 
which different lymphoma cell lines undergo opsonization 
with rituximab and ofatumumab, showed that morphologic 
membranous changes such as ‘blebbing’ and ‘streamers’, 
which are directly associated with complement-induced 
death, appeared more quickly with ofatumumab-exposed cell 
lines than with rituximab (114 vs 418 seconds, respectively). 
Importantly, ofatumumab showed activity against cell lines 
with high levels of CD55 and CD59, which are complement 
The CD20 molecule
Rituximab
Large loop
B-cell membrane
Small loop
Ofatumumab
Figure  The CD20 molecule structure. Ofatumumab binds to a different epitope (small loop) than rituximab (large loop).Journal of Blood Medicine 2010:1
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inactivating molecules; rituximab did not show activity even 
after several hours of incubation.25
Pharmacokinetic studies with ofatumumab were under-
taken in lymphoma cell lines, mice and monkeys.26 Using 
Daudi cells, CDC was seen at levels of 0.13 µg/mL with a 
full target saturation achieved at levels of 5 µg/mL; no further 
increase in CDC was seen with higher doses of ofatumumab. 
In a xenograft model, control mice developed lymphoma 
13 days after injection of Daudi cells while lymphoma devel-
oped 3 to 4 weeks later in mice exposed to ofatumumab at a 
dose of 0.5 mg/kg. Tumor growth was seen when ofatumumab 
levels were less than 0.4 µg/mL. In Cynomolgus monkeys, 
which have a CD20 molecule very similar to humans, a total 
B-cell depletion was observed immediately after exposure to 
ofatumumab with a full recovery of B-cells in 96 to 136 days. 
The authors concluded that concentrations of 50 µg/dL and 
5 to 10 µg/dL were needed to obtain and maintain the effect 
of ofatumumab in B-cells, respectively.
Safety and tolerability  
of ofatumumab
A phase I/II trial conducted by Coiffier and colleagues 
addressed the issue of safety and tolerability of ofatumumab 
in relapsed or refractory CLL.27 This trial analyzed 33 patients 
and divided them into 3 cohorts receiving different doses 
of ofatumumab; cohort A (n = 3) received the first infusion 
of 100 mg and 3 subsequent infusions of 500 mg; cohort B 
(n = 3) received a first infusion of 300 mg and 3 subsequent 
infusions of 1000 mg; and cohort C (n = 27) received a first 
infusion of 500 mg and 3 subsequent infusions of 2000 mg. 
The large majority of the patients (97%) received all four 
infusions. The results of the analysis demonstrated that 
27 patients reported 246 adverse events of which 7% were 
grade 3 or 4. Of all the adverse events, 61% were deemed 
related to treatment, the majority of which were reported on 
the day of infusion. This toxicity was noted to be similar to 
rituximab-related infusion reactions in CLL patients. Other 
notable serious adverse events included infections (51%) 
consisting of herpes zoster, pneumonia, sinusitis; hemato-
logic toxicity (15%) consisting of neutropenia and hemolytic 
anemia; angina pectoris (3%); hepatitis (3%); carotid artery 
stenosis (3%); and interstitial lung disease (3%). Of the 
serious toxicities (grade 3 and 4) only 5 were considered 
treatment-related, herpes zoster, neutropenia, interstitial lung 
disease and hepatitis.
In a phase II collaborative international effort,28 similar 
adverse effects were noted. The most common adverse events 
were first infusion-related reactions with an incidence of 38% 
to 46%; the incidence of grade 3 events was 3% to 7%. The 
incidence of infusion-related reactions decreases greatly with 
subsequent infusions. The most common grade 3 or 4 events 
were infections (25% to 27%), neutropenia (10% to 12%) and 
anemia (4% to 8%). Early death occurred in 5 patients but 
none were related to the administration of therapy. Although 
a potential concern, there was no evidence of development of 
human anti-human antibodies against ofatumumab.
Efficacy studies
Phase i/ii studies
The initial dose-escalation study, Hx-CD20-402, was a phase 
I/II trial in which 3 doses of ofatumumab were administered 
to 33 patients with relapsed or refractory CLL.27 The results 
at the conclusion of this study demonstrated an overall 
response rate (ORR) at 19 weeks after therapy of 44%. The 
ORR per cohort was as follows: Cohort A 33% (n = 1), 
cohort B 0% and cohort C 50% (n = 13). From the patients 
previously treated with rituximab (n = 7), alemtuzumab 
(n = 6) and or fludarabine (n = 20), seven responded to 
treatment. However, not all responses were sustained and 
at week 19 only 9 patients (27%) had sustained responses. 
When response was analyzed by hematologic parameters: 
6/7 anemic patients showed improvement (1 cohort B and 
5 cohort C); 8/9 had improvement with thrombocytopenia; 
bone marrow evaluation: 11 in cohort C, of which 8 who 
demonstrated response to treatment the median percentage 
of marrow lymphocytes decreased from 78% to 50% after 
treatment and 3 patients had less than 30%; and on analysis 
of the malignant population of CD5+/CD19+ B-cells in the 
periphery in cohort C, there was a median 55% reduction 
observed after the first infusion; after the fourth infusion the 
percentage reduction from baseline was 97% (range 15% to 
100%) and sustained until week 24.
A second study, Hx-CD20-406, is an international multi-
center phase II study that is currently ongoing but data from 
the planned 12-month interim analysis have been released.28–30 
Ofatumumab was used in 59 patients with refractory DR and 
79 patients with BFR CLL. In this study, patients received 
8 weekly infusions of ofatumumab followed by 4 monthly 
infusions (Dose 1, 300 mg; Doses 2–12, 2000 mg); 54% of 
the patients received all 12 infusions and 90% received 8 
infusions. The median prior therapy exposure was 5 (DR) and 
4 regimens (BFR), with a prior rituximab exposure of 59% 
(DR) and 43% (BFR). The final results published included an 
ORR of 58% (n = 34) for the DR group and 47% (n = 30) for 
the BFR group. The median time until next CLL treatment 
was 8 to 9 months and the median OS was about 15.4 months Journal of Blood Medicine 2010:1
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for the DR group and 13.7 months for the BFR group. At the 
landmark analysis at week 12, a clinical response significantly 
correlated with longer survival for both DR and BFR groups. 
Additionally, in patients not achieving a formal response by 
National Cancer Institute-sponsored Working Group (NCI-
WG) criteria, clinical benefit was observed with resolution 
of symptoms and improvement in thrombocytopenia and 
anemia. Interestingly, similar response rates were observed in 
CLL patients with or without prior exposure to rituximab.
Ongoing phase II trials include a re-treatment and main-
tenance with ofatumumab for patients who have progressed 
after an initial response to ofatumumab (NCT00802737) 
and the combination of ofatumumab with fludarabine and 
cyclophosphamide in previously untreated CLL patients 
(NCT00410163);31 the latter is a randomized phase II trial 
comparing 2 doses of ofatumumab, 500 mg and 1000 mg, 
given in combination with fludarabine and cyclophospha-
mide. These combinations have shown great activity with 
ORR of 77% and 73% and CR rates of 32% and 50% for 
the 500-mg and 1000-mg arms, respectively.32 Planned 
phase II studies include the combination of ofatumumab 
and bendamustine (NCT01010568) and the combination of 
ofatumumab and lenalidomide (NCT01002755) in previously 
treated CLL patients.31
Phase iii studies
Two randomized controlled trials are ongoing.31 Chlorambucil 
with or without ofatumumab is being evaluated in untreated 
patients with CLL (COMPLEMENT 1; NCT00748189). 
Enrollment started in December 2008 with an estimated 
goal study population of 444 patients. The second study will 
evaluate the combination of fludarabine and cyclophospha-
mide with or without ofatumumab in previously treated CLL 
patients (NCT00824265). Enrollment started in March 2009 
and aims to prospectively enroll 352 patients.
Patient perspectives
On October 26, 2009 the FDA announced the approval of 
ofatumumab for its use in patients with refractory or relapsed 
CLL that have failed fludarabine and alemtuzumab-based 
regimens.33 Since ofatumumab has a benign side effect pro-
file along with lower rates of infusion-related reactions and 
faster infusions than rituximab, good compliance and higher 
patient satisfaction rates are expected.
Conclusions
As CLL remains an incurable disease with the current treat-
ment options, the pursuit of newer drugs and combination 
regimens is warranted. The goal of our therapy in CLL should 
be focused on obtaining durable responses and prolonging 
survival while improving or, at least, not affecting the qual-
ity of life of the patients. Clinicians have at hand a myriad 
of different available therapies and the rational use of these 
could be a challenge and needs careful consideration and 
analysis. The available therapies for CLL will give evidence-
based hematologists and oncologists the opportunity to put 
into practice what we call the art of medicine.
With an improved understanding of the biology of can-
cer, multiple pathways are being discovered, evaluated and 
targeted with drugs struggling to be tried in well-planned 
studies. Unfortunately, only a handful of these regimens 
will be valued enough to get into large randomized trials. 
The CD20 molecule has arisen as an almost perfect target 
since it is well anchored to the B-cell membrane and does 
not undergo shedding or internalization. Furthermore, CD20 
is expressed only in B-cells giving anti-CD20 MAbs a speci-
ficity rarely seen with other drugs, representing the goal of 
the so-called targeted therapy. Not without surprise, several 
anti-CD20 MAbs continue undergoing clinical development. 
Few examples include veltuzumab (IMMU-106), which is a 
humanized anti-CD20 MAb under development by Immuno-
medics Inc., and afutuzumab (GA-101), a third-generation 
anti-CD20 MAb with increased ADCC activity, currently 
under development by Genentech and Biogen Idec Inc. These 
drugs are undergoing phase I/II trials and have shown to be 
both safe and efficacious in patients with lymphoprolifera-
tive disorders.34,35
Ofatumumab, a second-generation anti-CD20 MAb, 
has emerged as a therapeutic option in patients with CLL. 
Several clinical trials have shown efficacy in frontline and 
relapsed settings, even after rituximab-containing regimens. 
Most importantly, responses and clinical improvements have 
been seen in patients with disease resistant to fludarabine and 
alemtuzumab and patients with bulky lymphadenopathy. 
It is worth emphasizing that these effects have been seen 
with ofatumumab administered as a single agent. The recent 
approval of ofatumumab for the treatment of CLL patients who 
have failed fludarabine- and alemtuzumab-containing regi-
mens emphasizes its use as a third- or fourth-line therapy.
However, ofatumumab has a great potential for further 
development. An ongoing trial is evaluating the addition of 
ofatumumab to chlorambucil in untreated CLL patients and 
a second trial is studying its combination with fludarabine 
and cyclophosphamide in previously treated CLL patients. 
It is likely that, if these trials show positive results, ofatu-
mumab will obtain approval at earlier stages of therapy. If the Journal of Blood Medicine 2010:1
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pre-clinical characteristics of ofatumumab such as stronger 
CDC and reduced off-rates will translate into a superior 
response or survival rates than rituximab is unclear at the 
moment and will need to be addressed in carefully designed 
comparative trials. Practitioners have used rituximab for 
several years with a high level of comfort; hence, it will be 
difficult to replace it unless the new therapy is associated with 
a better efficacy rate and safer toxicity profile. So far, infu-
sion-related reactions seemed to occur less frequently with 
ofatumumab, and given its fully human structure it should be 
less immunogenic, allowing for faster intravenous infusions. 
Interesting concepts such as re-treatment and maintenance 
therapy with ofatumumab are under investigation; appropri-
ately large study populations and long follow-up time are 
necessary in order to guarantee reliable conclusions.
Several agents targeting novel pathways are undergo-
ing clinical development in patients with CLL. These will 
make available to us, the practitioners, potential combina-
tions that hopefully will translate, if not into a cure, into 
better, more durable responses and longer survival times. 
Personalization of therapy seems inevitable for patients with 
CLL, most of which will experience a protracted clinical 
course and survival measured in several years. Therefore, 
the careful tailoring of our therapies should allow us to 
obtain such responses without affecting the quality of life 
of our patients.
In summary, ofatumumab, thus far, has demonstrated 
promising potential as a therapeutic option in relapsed CLL, 
even in patients who have already failed the most effective 
available therapies. Careful design, execution and analysis 
of prospective studies will be necessary to further refine and 
define the role of ofatumumab in standard clinical care in 
patients with CLL.
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